• D Gur, G Hascelik, N Aydin, M Telli, M Gültekin, D Ogülnç, O A Arikan, S Uysal, A Yaman, F Kibar, Z Gülay, B Sumerkan, D Esel, C B Kayacan, Z Aktas, G Soyletir, G Altinkanat, B Durupinar, O Darka, Y Akgün, B Yayla, S Gedikoglu, M Sinirtas, M Berktas, and G Yaman.
• Hacettepe University, School of Medicine, Clinical Microbiology Laboartory, Ankara, Turkey.
• J Chemother. 2009 Aug 1;21(4):383-9.

AbstractResistance rates to amikacin, ciprofloxacin, ceftazidime, cefepime, imipenem, cefoperazone/sulbactam and piperacillin/tazobactam in Escherichia coli (n= 438), Klebsiella pneumoniae (n= 444), Pseudomonas aeruginosa (n= 210) and Acinetobacter baumanni (n=200) were determined with e-test in a multicenter surveillance study (Hitit-2) in 2007. ESBL production in Escherichia coli and K. pneumoniae was investigated following the CLSI guidelines. Overall 42.0% of E.coli and 41.4% of K. pneumoniae were ESBL producers. In E. coli , resistance to imipenem was not observed, resistance to ciprofloxacin and amikacin was 58.0% and 5.5% respectively. In K. pneumoniae resistance to imipenem, ciprofloxacin and amikacin was 3.1%, 17.8% 12.4% respectively. In P. aeruginosa the lowest rate of resistance was observed with piperacillin/tazobactam (18.1%). A. baumanni isolates were highly resistant to all the antimicrobial agents, the lowest level of resistance was observed against cefoperazone/sulbactam (52.0%) followed by imipenem (55.5%). this study showed that resistance rates to antimicrobials are high in nosocomial isolates and show variations among the centers.

19 keywords...

hide…